News | May 16, 2021
Aarti Drugs Q4FY21 consolidated net profit drops to Rs. 51.65 Cr
Aarti Drugs has reported total income of Rs.2159.30 crores during the 12 months period ended March 31, 2021
Aarti Drugs has reported total income of Rs.2159.30 crores during the 12 months period ended March 31, 2021
The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day
The company is working closely with its six manufacturing partners in India
The company has reported total income of Rs.19425.58 crores during FY ended March 31, 2021
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
Subscribe To Our Newsletter & Stay Updated
